Superficial mycotic infections of skin and nails are the most common diseases seen in our daily practice and the main causative groups are dermatophytes, yeasts and moulds. The degree of immunosuppression and the number of immunosuppressed patients are increasing at an unprecendented pace, hence the management of dermatophytoses will be a challenge to mankind in the years to come.The increasing number of antifungal agents, reformulations of existing agents and novel treatment strategies have all improved the management of fungal infections, but still the infections are associated with high mortality. Currently, topical azoles and allylamines are used for the treatment of Cutaneous mycoses with disadvantages like long duration of therapy, which leads to poor compliance and a high relapse rate. Assessment of efficacy, Quality of life (QOL) and Medication adherence are important issues in all areas of clinical medicine, including dermatology. Here the clinical efficacy was assessed based on signs and symptoms severity score and global clinical response, Dermatology life quality by Finlay and Khan's 10 question Dermatology Life Quality Index (DLQI) and adherence by medication adherence questionnnaire. Both Terbinafine (250-500 mg/day for 2-6 weeks) and Itraconazole (100-200 mg/day for 2-4 weeks) appear to be effective for limited disease (tinea corporis/cruris/pedis). However, an appropriate dose and duration of administration which can produce mycologic cure and prevent recurrence remains elusive. This review also highlights the huge research gaps in the management of cutaneous dermatophytosis which need to be plugged to provide better and effective care to the patients.
INTRODUCTION:
Superficial mycotic infections of skin and nails are the most common diseases seen in our daily practice. The main causative groups are dermatophytes, yeasts and moulds. [1] The dermatophytes that usually cause are : Microsporum, Trichophyton, and Epidermophyton. Dermatophytes grow on keratin and therefore cause diseases in body sites wherein keratin is present which include the skin surface, hair and nail. The skin surface is the habitat of most of these fungi and is liable to environmental contamination. According to the sites of skin involved dermatophyte infections are subclassified as Tinea faciei: face; Tinea manuum: hands; Tinea corporis: glabrous skin, Tinea cruris: crural folds; Tinea pedis: feet; Tinea capitis: scalp and Tinea unguium: nails.Although dermatophytoses cause morbidity and posses major health problem , it does not cause mortality [1] . No race in any geographical location is totally free from dermatophytoses [1] .
Given that, the degree of immunosuppression and the number of immunosuppresed patients are increasing at an unprecendented pace, the management of dermatophytoses will be a challenge to mankind in the years to come. The choice of an antifungal agent should be based on an accurate diagnosis [2] .Currently, topical azoles and allylamines are used for the treatment of Cutaneous mycoses with disadvantages like long duration of therapy, which leads to poor compliance and a high relapse rate. Some of the newer agents require only once-daily application and shorter courses of treatment, and are associated with lower relapse rates [2] . According to World Health Organization (WHO), the prevalence rate of superficial mycotic infection worldwide has been found to be 20-25%. It is more prevalent in tropical and subtropical countries like India where the heat and humidity is high for most part of the year [4] .The causative species vary with geographic region and some species are distributed worldwide such as Trichophyton rubrum, T. mentagrophytes var. interdigitale, Microsporum canis, and Epidermophyton floccosum. Others have partial geographic restriction, such as T schoenleinii (Eurasia, Africa), T soudanense (Africa), T violaceum (Africa, Asia, and Europe), and T concentricum (Pacific Islands, Far East, and India). Most cases of tinea unguium, tinea cruris, tinea corporis, and tinea pedis are caused by T rubrum, which is the commonest dermatophyte in most developed countries as well as in urban areas of some developing countries. Dermatophyte infections can be acquired most commonly from another person , from animals such as puppies or kittens and least commonly from soil. Recent development in understanding the pathophysiology of dermatophytosis have confirmed the central role of cellmediated immunity in countering these infections. Hence, a lack of delayed hypersensitivity reaction in presence of a positive immediate hypersensitivity (IH) response to trichophytin antigen points toward the chronicity of disease. The laboratory diagnostic approach will involve 1) wet mount KOH examination that can be performed rapidly at the "bed-side" with or without staining (e.g. by Parker's blue black ink, chlorazole black), 2) culture for proper species identification. The scales from active lesions produced by skin scraping can be collected. Repeated sampling is sometimes required to isolate the causative fungi 
EFFICACY OF ANTIFUNGAL TREATMENT
Assessment of efficacy of antifungal treatment is essential in the present scenario.The main aim of the study [2] is to compare the efficacy of newer antifungals like Luliconazole, Amorolfine, eberconazole, sertaconazole and terbinafine cutaneous mycoses (commonest presentation-tinea corporis). [2] Here the clinical efficacy was assessed on signs and symptoms severity score of the target lesion. These signs and symptoms were scored as: 0=absent (none), 1= mild (barely perceptible), 2=moderate (distinctive presence), and 3= severe (marked, intense). The signs and symptoms that were evaluated were erythema, desquamation, pruritis, vesicles, and encrustation. Global clinical response was also evaluated by the investigator using the following 6 point scale: -1= exacerbation (flareup at the site of treatment), 0=unchanged, 1= mild improvement (<50% clearance), 2= moderate improvement (50% to 75% clearance), 3= excellent improvement (75% to 100% clearance), 4= cleared (100% clearance). The efficacy is assessed based on the parameters: 1) KOH test: A negative KOH preparation at the end of the study period was considered as mycological cure. 2) Change in the signs and symptoms score .Thereby the efficacy is assessed by the number of patients who has maximum improvement in signs and symptoms and those who has complete cure. [2] 
QUALITY OF LIFE OF PATIENTS WITH MYCOTIC INFECTIONS
Measures of quality of life (QOL) have particular significance for dermatological conditions as, although not generally lifethreatening, they frequently have a major impact on patient's psychosocial state, social relationships and everyday activities. Finlay and Khan's 10 question Dermatology Life Quality Index (DLQI), which is designed as a simple, compact uniform measure, for use as an assessment tool in routine daily clinical practice, and includes two questions relating to symptoms and feelings. It can be quickly selfcompleted and provide information that complements traditional clinical indicators. These scales should assist in informing treatment decisions by identifying impacts of different skin conditions and variations in responses among social and cultural groups, as well as guiding priorities for services within the specialty. The DQOLS are based on a greater number of items, comprising psychosocial, physical activities and symptom scales, and place considerable emphasis on the psychosocial impact of skin conditions. [3] 
ADHERENCE OF PATIENTS TO ANTIFUNGAL REGIMEN:
Medication adherence is an important issue in all areas of clinical medicine, including dermatology. In dermatology, medication adherence for dermatomycosis is known to decrease with the duration of treatment and the frequency of applications required each day, particularly once symptoms have disappeared. Simpler dosing regimens are sought for the treatment of cutaneous fungal infections. It is hypothesized that its prolonged dermal retention may translate into the need for less frequent application for successful treatment in clinical practice. Possible consequences of nonadherence in clinical practice include death, reduced treatment benefits, biased assessments of treatment efficacy, and increased healthcare costs; 33 to 69 percent of medication-related hospital admissions in the United States are the result of poor adherence. Multiple possible causes for patient nonadherence have been postulated. [5 ] They include the following problems with the therapy, such as side effects; poor instructions given to the patient by the prescriber; poor physician-patient relationship; poor memory on the part of patients; and patients' inability to pay for medications. With short-term treatment, adherence can usually be enhanced with patient education and followup by telephone or e-mail, but interventions capable of increasing adherence in patients with chronic health problems tend to be complex, involving combinations of patient education, reminders, family therapy, psychological therapy, crisis intervention, and close followup. As one report has noted, even the most effective interventions in patient's habits do not lead to large improvements in adherence or treatment outcome. 
